Clinical Trials Logo
  1. Home
  2. Safety and Tolerability
  3. NCT03817346

Study of Ascending Single Oral Dose of GT-002 in Healthy Volunteers — GAB-001  

Safety and Tolerability Clinical Trial

Official title:
A Phase I, Randomised, Double-blind, Placebo-controlled Study in Healthy Male Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of Ascending Single Oral Doses of GT-002

Clinical Trial Summary

This study does not target any disease or condition in itself, but is evaluating the safety, tolerability and pharmacokinetics of single oral doses of GT-002 in the setting of healthy volunteers.

A longer-term objective is to apply the findings from this study to design and later conduct a clinical development programme of GT-002 as a medication to treat schizophrenia.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03817346
Study type Interventional
Source Gabather AB
Contact
Status Completed
Phase Phase 1
Start date December 17, 2018
Completion date May 31, 2019
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT06000891 - A Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570 Phase 1
Active, not recruiting NCT05997641 - Evaluating the Safety, Tolerability, and Pharmacokinetics of DF-003 in Healthy Subjects Phase 1
Completed NCT06181760 - A Study to Evaluate the Safety of Fenretinide in Healthy Volunteers Phase 1
Recruiting NCT05907382 - Safety, Tolerability of JMKX003002 in Phase 1 Study in Healthy Subjects Phase 1
Completed NCT01952548 - Study Comparing the Pharmacokinetics, Pharmacodynamics, and Safety of K-312 in Healthy Adult Volunteers Phase 1
Completed NCT05431634 - Multiple Dose Study to Determine Safety and Tolerability of ESK-001 in Healthy Participants Phase 1
Recruiting NCT06331884 - Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics/-Dynamics of AK1967 (Procizumab) Phase 1
Completed NCT03046589 - DP13 SAD & MAD in Healthy Male Subjects Phase 1
Recruiting NCT06079541 - Phase 1 Clinical Study of JMKX003142 Tablets Phase 1
Completed NCT05223660 - A Phase I Pharmacokinetics Study for KT07 Capsule Phase 1
Completed NCT01907867 - Pharmacokinetic Profile in Plasma and Epithelial Lining Fluid of Finafloxacin Phase 1
Completed NCT03809052 - A First in Human Study to Evaluate the Safety, Tolerability and PK of GB1211 in Healthy Subjects Phase 1
Completed NCT03853421 - Placebo-controlled Study to Determine the Safety and Tolerability of Subcutaneous Doses of Sevuparin Phase 1
Terminated NCT03307512 - PK and PD Profile of Dance 501 in Healthy, Non-diabetic Subjects With Mild to Moderate Asthma or COPD Phase 2
Completed NCT03685708 - HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I) Phase 2
Completed NCT03702231 - Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I) Phase 2
Active, not recruiting NCT01226316 - Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules Phase 1
Completed NCT05451667 - Single-Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of YJ001 in Healthy Volunteers Phase 1
Completed NCT02029482 - Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-128800 in Healthy Subjects Phase 1